A Plus Biotechnology Co., Ltd. (TPE:6918)
Taiwan · Delayed Price · Currency is TWD 74.50
+0.50 (0.68%)
Aug 26, 2026, 1:30 PM CST
A Plus Biotechnology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,521 | 2,956 | 2,444 | 1,380 | - | - | |
Market Cap Growth | -25.05% | 20.95% | 77.04% | - | - | - |
Enterprise Value | 2,203 | 2,465 | 2,205 | 1,246 | - | - |
Last Close Price | 74.00 | 80.47 | 72.81 | 39.88 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 13.71 | 17.45 | 16.18 | - | - | - |
PS Ratio | 2.84 | 3.54 | 3.18 | 2.05 | - | - |
PB Ratio | 2.10 | 2.34 | 2.66 | 1.67 | - | - |
P/TBV Ratio | 2.11 | 2.35 | 2.68 | 1.68 | - | - |
P/FCF Ratio | 78.41 | 20.41 | 16.07 | 9.22 | - | - |
P/OCF Ratio | 14.87 | 18.60 | 15.18 | 8.68 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.48 | 2.95 | 2.87 | 1.85 | - | - |
EV/EBITDA Ratio | 8.72 | 10.96 | 11.17 | 6.87 | - | - |
EV/EBIT Ratio | 9.77 | 11.81 | 12.08 | 7.44 | - | - |
EV/FCF Ratio | 68.51 | 17.02 | 14.50 | 8.32 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.13 | 0.08 | 0.12 | 0.14 | 0.15 | 0.24 |
Debt / EBITDA Ratio | 0.67 | 0.41 | 0.52 | 0.59 | 1.43 | 3.01 |
Debt / FCF Ratio | 4.99 | 0.66 | 0.70 | 0.76 | 5.14 | - |
Net Debt / Equity Ratio | -0.27 | -0.40 | -0.31 | -0.25 | -0.12 | -0.12 |
Net Debt / EBITDA Ratio | -1.39 | -2.28 | -1.44 | -1.14 | -1.17 | -1.48 |
Net Debt / FCF Ratio | -9.99 | -3.54 | -1.87 | -1.38 | -4.22 | 0.60 |
Asset Turnover | 0.59 | 0.61 | 0.68 | 0.60 | 0.52 | 0.51 |
Inventory Turnover | 0.88 | 0.82 | 0.82 | 0.74 | 0.81 | 0.68 |
Quick Ratio | 3.61 | 3.97 | 3.52 | 3.24 | 2.24 | 2.18 |
Current Ratio | 5.83 | 5.99 | 5.49 | 5.39 | 4.08 | 3.74 |
Return on Equity (ROE) | 15.50% | 15.52% | 17.29% | -1.32% | 5.31% | 4.41% |
Return on Assets (ROA) | 8.87% | 9.57% | 10.14% | 9.32% | 3.52% | 2.73% |
Return on Invested Capital (ROIC) | 21.36% | 23.59% | 23.39% | -89.57% | 5.94% | 5.72% |
Return on Capital Employed (ROCE) | 15.60% | 15.40% | 18.00% | 18.00% | 6.70% | 4.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.37% | 5.73% | 6.18% | -0.82% | - | - |
FCF Yield | 1.28% | 4.90% | 6.22% | 10.85% | - | - |
Dividend Yield | 6.72% | 6.21% | 5.49% | 6.77% | - | - |
Payout Ratio | 91.69% | 71.96% | 53.95% | - | 33.34% | 43.48% |
Buyback Yield / Dilution | -11.74% | -8.36% | -0.37% | 0.71% | -5.45% | -0.95% |
Total Shareholder Return | -5.02% | -2.15% | 5.12% | 7.48% | -5.45% | -0.95% |